Ventyx Biosciences Stock Performance
| VTYX Stock | USD 2.02 0.13 6.88% |
The entity has a beta of 0.72, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Ventyx Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Ventyx Biosciences is expected to be smaller as well. At this point, Ventyx Biosciences has a negative expected return of -0.0722%. Please make sure to validate Ventyx Biosciences' accumulation distribution, and the relationship between the potential upside and day median price , to decide if Ventyx Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Ventyx Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Ventyx Biosciences is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 6.88 | Five Day Return (2.42) | Year To Date Return (5.61) | Ten Year Return (90.39) | All Time Return (90.39) |
1 | Disposition of 1651 shares by John Nuss of Ventyx Biosciences at 5.4034 subject to Rule 16b-3 | 11/12/2024 |
2 | Ventyx Biosciences stock hits 52-week low at 1.78 amid market shifts - Investing.com India | 11/18/2024 |
3 | Acquisition by Raju Mohan of 238248 shares of Ventyx Biosciences at 1.8256 subject to Rule 16b-3 | 11/22/2024 |
4 | Acquisition by Raju Mohan of 261752 shares of Ventyx Biosciences at 2.0055 subject to Rule 16b-3 | 11/25/2024 |
5 | Insider Activity Recap Mondays Top Buys and Sells in US Stocks | 11/26/2024 |
6 | Sio Capital Management LLC Raises Stock Holdings in Ventyx Biosciences, Inc. - MarketBeat | 11/29/2024 |
7 | Disposition of 193557 shares by John Nuss of Ventyx Biosciences at 0.2 subject to Rule 16b-3 | 12/10/2024 |
8 | VENTYX ALERT Bragar Eagel Squire, P.C. is Investigating Ventyx Biosciences, Inc. ... | 12/11/2024 |
9 | Disposition of 116668 shares by Raju Mohan of Ventyx Biosciences subject to Rule 16b-3 | 12/17/2024 |
10 | Disposition of 13161 shares by John Nuss of Ventyx Biosciences at 2.2553 subject to Rule 16b-3 | 12/19/2024 |
11 | Acquisition by Gujrathi Sheila of 130000 shares of Ventyx Biosciences at 2.3121 subject to Rule 16b-3 | 12/23/2024 |
12 | Disposition of 21119 shares by John Nuss of Ventyx Biosciences at 2.36 subject to Rule 16b-3 | 12/27/2024 |
13 | Insider Sell John Nuss Sells 21,119 Shares of Ventyx Biosciences Inc | 12/31/2024 |
14 | Acquisition by Forman Mark S of 85000 shares of Ventyx Biosciences at 2.14 subject to Rule 16b-3 | 01/02/2025 |
15 | Acquisition by Gonzales Roy of 109200 shares of Ventyx Biosciences at 2.14 subject to Rule 16b-3 | 01/03/2025 |
16 | Were Keeping An Eye On Ventyx Biosciences Cash Burn Rate | 01/10/2025 |
17 | HC Wainwright Analysts Increase Earnings Estimates for VTYX - MarketBeat | 01/17/2025 |
| Begin Period Cash Flow | 64.8 M |
Ventyx |
Ventyx Biosciences Relative Risk vs. Return Landscape
If you would invest 239.00 in Ventyx Biosciences on October 21, 2024 and sell it today you would lose (37.00) from holding Ventyx Biosciences or give up 15.48% of portfolio value over 90 days. Ventyx Biosciences is currently does not generate positive expected returns and assumes 6.5697% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than Ventyx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ventyx Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ventyx Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ventyx Biosciences, and traders can use it to determine the average amount a Ventyx Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.011
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VTYX |
Estimated Market Risk
| 6.57 actual daily | 58 58% of assets are less volatile |
Expected Return
| -0.07 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Ventyx Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ventyx Biosciences by adding Ventyx Biosciences to a well-diversified portfolio.
Ventyx Biosciences Fundamentals Growth
Ventyx Stock prices reflect investors' perceptions of the future prospects and financial health of Ventyx Biosciences, and Ventyx Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ventyx Stock performance.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | (120.95 M) | ||||
| Shares Outstanding | 70.71 M | ||||
| Price To Book | 0.51 X | ||||
| EBITDA | (207.84 M) | ||||
| Net Income | (192.96 M) | ||||
| Cash And Equivalents | 250.45 M | ||||
| Cash Per Share | 4.92 X | ||||
| Total Debt | 12.51 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.27 X | ||||
| Book Value Per Share | 3.94 X | ||||
| Cash Flow From Operations | (166.52 M) | ||||
| Earnings Per Share | (2.35) X | ||||
| Market Capitalization | 142.84 M | ||||
| Total Asset | 277.69 M | ||||
| Retained Earnings | (419.19 M) | ||||
| Working Capital | 242.08 M | ||||
About Ventyx Biosciences Performance
Evaluating Ventyx Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Ventyx Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ventyx Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.63) | (0.66) | |
| Return On Capital Employed | (0.94) | (0.89) | |
| Return On Assets | (0.63) | (0.66) | |
| Return On Equity | (0.91) | (0.86) |
Things to note about Ventyx Biosciences performance evaluation
Checking the ongoing alerts about Ventyx Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ventyx Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ventyx Biosciences generated a negative expected return over the last 90 days | |
| Ventyx Biosciences has high historical volatility and very poor performance | |
| Net Loss for the year was (192.96 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ventyx Biosciences currently holds about 250.45 M in cash with (166.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.92, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Ventyx Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: HC Wainwright Analysts Increase Earnings Estimates for VTYX - MarketBeat |
- Analyzing Ventyx Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ventyx Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Ventyx Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ventyx Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ventyx Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ventyx Biosciences' stock. These opinions can provide insight into Ventyx Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Ventyx Stock Analysis
When running Ventyx Biosciences' price analysis, check to measure Ventyx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventyx Biosciences is operating at the current time. Most of Ventyx Biosciences' value examination focuses on studying past and present price action to predict the probability of Ventyx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventyx Biosciences' price. Additionally, you may evaluate how the addition of Ventyx Biosciences to your portfolios can decrease your overall portfolio volatility.